Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 27,297 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 27,297 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $0.92, for a total transaction of $25,113.24. Following the completion of the sale, the director directly owned 3,287,551 shares in the company, valued at approximately $3,024,546.92. This represents a 0.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $55,852.16.
• On Friday, November 21st, Luke Evnin sold 41,287 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total value of $34,268.21.
• On Thursday, November 20th, Luke Evnin sold 26,411 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $23,505.79.
• On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $40,012.04.
• On Tuesday, November 18th, Luke Evnin sold 33,776 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $31,411.68.
• On Monday, November 17th, Luke Evnin sold 36,621 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total transaction of $34,789.95.
• On Friday, November 14th, Luke Evnin sold 39,560 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $36,790.80.
• On Thursday, November 13th, Luke Evnin sold 58,372 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $57,204.56.
• On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $28,450.09.
• On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total value of $40,832.52.

Werewolf Therapeutics Stock Down 6.8%

Shares of Werewolf Therapeutics stock traded down $0.07 during trading on Tuesday, reaching $0.91. The company’s stock had a trading volume of 461,162 shares, compared to its average volume of 505,004. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The company has a 50-day simple moving average of $1.52 and a two-hundred day simple moving average of $1.34. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The company has a market cap of $44.19 million, a price-to-earnings ratio of -0.56 and a beta of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on HOWL. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Bank of America cut their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, JMP Securities lowered their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Werewolf Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $7.75.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors have recently modified their holdings of the stock. MPM Asset Management LLC lifted its holdings in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after buying an additional 25,688 shares during the period. MPM Bioimpact LLC raised its position in Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares in the last quarter. Bank of America Corp DE lifted its holdings in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares during the period. Vanguard Group Inc. boosted its position in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $409,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.